Effects of combined dietary chromium(III) propionate complex and thiamine supplementation on insulin sensitivity, blood biochemical indices, and mineral levels in high-fructose-fed rats.
Insulin resistance is the first step in glucose intolerance and the development of type 2 diabetes mellitus, thus effective prevention strategies should also include dietary interventions to enhance insulin sensitivity. Nutrients, such as microelement chromium(III) and thiamine, play regulatory roles in carbohydrate metabolism. The objective of this study was to evaluate the insulin-sensitizing potential of the combined supplementary chromium(III) propionate complex (CrProp) and thiamine in insulin resistance animal model (rats fed a high-fructose diet). The experiment was carried out on 40 nine-week-old male Wistar rats divided into five groups (eight animals each). Animals were fed ad libitum: the control diet (AIN-93 M) and high-fructose diets with and without a combination of two levels of CrProp (0.1 and 1 mg Cr/kg body mass/day) and two levels of thiamine (0.5 and 10 mg/kg body mass/day) for 8 weeks. At the end of the experiment rats were sacrificed to collect blood and internal organs for analyses of blood biochemical and hematologic indices as well as tissular microelement levels that were measured using appropriate methods. It was found that both supplementary CrProp and thiamine (given alone) have significant insulin-sensitizing and moderate blood-lipid-lowering properties, while the combined supplementation with these agents does not give synergistic effects in insulin-resistant rats. CrProp given separately increased kidney Cu and Cr levels, while thiamine alone increased hepatic Cu contents and decreased renal Zn and Cu contents.
Department of Human Nutrition and Hygiene, Poznan University of Life Sciences, 31 Wojska Polskiego, 60-624, Poznan, Poland. ekrol@up.poznan.pl
Ewelina
E
Król
Zbigniew
Z
Krejpcio
Sławomir
S
Michalak
Rafał W
RW
Wójciak
Paweł
P
Bogdański
D000818:Animals; D002857:Chromium / Q000008:administration & dosage / Q000009:adverse effects / Q000378:metabolism / Q000627:therapeutic use*; D003300:Copper / Q000378:metabolism; D019587:Dietary Supplements; D005632:Fructose / Q000009:adverse effects; D018149:Glucose Intolerance / Q000178:diet therapy* / Q000209:etiology / Q000378:metabolism / Q000503:physiopathology; D006943:Hyperglycemia / Q000517:prevention & control; D006949:Hyperlipidemias / Q000209:etiology / Q000517:prevention & control; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000378:metabolism / Q000627:therapeutic use*; D000960:Hypolipidemic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000378:metabolism / Q000627:therapeutic use; D007333:Insulin Resistance; D007668:Kidney / Q000378:metabolism; D008099:Liver / Q000378:metabolism; D008297:Male; D011236:Prediabetic State / Q000178:diet therapy* / Q000209:etiology / Q000378:metabolism / Q000503:physiopathology; D011422:Propionates / Q000008:administration & dosage; D051381:Rats; D017208:Rats, Wistar; D013831:Thiamine / Q000008:administration & dosage / Q000009:adverse effects / Q000378:metabolism / Q000627:therapeutic use*; D014018:Tissue Distribution; D015032:Zinc / Q000378:metabolism
D007004:Hypoglycemic Agents; D000960:Hypolipidemic Agents; D011422:Propionates; D002857:Chromium; D005632:Fructose; D003300:Copper; D015032:Zinc; C029658:propionic acid; D013831:Thiamine